



## **Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)**

June 4, 2018

WAYNE, Pa., June 04, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced that on June 1, 2018 the Compensation Committee of Aclaris' Board of Directors granted 3 restricted stock unit awards covering an aggregate of 7,100 shares of its common stock to 3 new employees under the Aclaris 2017 Inducement Plan. The restricted stock units were granted as inducements material to the new employees becoming employees of Aclaris in accordance with NASDAQ Listing Rule 5635(c)(4).

The 2017 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Aclaris (or following a bona fide period of non-employment), as an inducement material to such individuals entering into employment with Aclaris, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

Each restricted stock unit award will vest, and become exercisable (as applicable), as to twenty-five percent of the shares on each of the first, second, third, and fourth anniversaries of the recipient's start date, subject to each such employee's continued employment with Aclaris on such vesting dates. The restricted stock unit award is subject to the terms and conditions of Aclaris' 2017 Inducement Plan, and the terms and conditions of a restricted stock unit agreement, as applicable, covering the grant.

### **About Aclaris Therapeutics, Inc.**

Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both aesthetic and medical, and immunology. Aclaris' focus on market segments with no FDA-approved medications or where treatment gaps exist has resulted in the first FDA-approved treatment for raised seborrheic keratoses and several clinical programs to develop medications for the potential treatment of common warts, alopecia areata, and vitiligo. For additional information, please visit [www.aclaristx.com](http://www.aclaristx.com) and follow Aclaris on LinkedIn.

Aclaris Contact  
Michael Tung, M.D.  
Senior Vice President  
Corporate Strategy/Investor Relations  
484-329-2140  
[mtung@aclaristx.com](mailto:mtung@aclaristx.com)



Source: Aclaris Therapeutics, Inc.